Back to Report Store Home

Transplant Complications Drug Development Pipeline Review, 2018

  • Published: Nov-2018
  • Report Code: GBIHC051IDB
  • Report Format: pdf

Description

List of Tables

Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD)

Table 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)

Table 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)

Table 4: Products under Development by Companies, Graft Versus Host Disease (GVHD)

Table 5: Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)

Table 6: Number of Products under Development for Liver Transplant Rejection

Table 7: Number of Products under Development by Companies, Liver Transplant Rejection

Table 8: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection

Table 9: Products under Development by Companies, Liver Transplant Rejection

Table 10: Products under Development by Universities/Institutes, Liver Transplant Rejection

Table 11: Number of Products under Development for Kidney Transplant Rejection

Table 12: Number of Products under Development by Companies, Kidney Transplant Rejection

Table 13: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection

Table 14: Products under Development by Companies, Kidney Transplant Rejection

Table 15: Products under Development by Universities/Institutes, Kidney Transplant Rejection

Table 16: Number of Products under Development for Lung Transplant Rejection

Table 17: Number of Products under Development by Companies, Lung Transplant Rejection

Table 18: Products under Development by Companies, Lung Transplant Rejection

Table 19: Number of Products by Stage and Target, Graft Versus Host Disease (GVHD)

Table 20: Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD)

Table 21: Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD)

Table 22: Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD)

Table 23: Number of Products by Stage and Target, Liver Transplant Rejection

Table 24: Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection

Table 25: Number of Products by Stage and Route of Administration, Liver Transplant Rejection

Table 26: Number of Products by Stage and Molecule Type, Liver Transplant Rejection

Table 27: Number of Products by Stage and Target, Kidney Transplant Rejection

Table 28: Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection

Table 29: Number of Products by Stage and Route of Administration, Kidney Transplant Rejection

Table 30: Number of Products by Stage and Molecule Type, Kidney Transplant Rejection

Table 31: Number of Products by Stage and Target, Lung Transplant Rejection

Table 32: Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection

Table 33: Number of Products by Stage and Route of Administration, Lung Transplant Rejection

Table 34: Number of Products by Stage and Molecule Type, Lung Transplant Rejection

Table 35: Graft Versus Host Disease (GVHD) – Pipeline by AbbVie Inc

Table 36: Graft Versus Host Disease (GVHD) – Pipeline by AbGenomics International Inc

Table 37: Graft Versus Host Disease (GVHD) – Pipeline by Amgen Inc

Table 38: Graft Versus Host Disease (GVHD) – Pipeline by AnaptysBio Inc

Table 39: Graft Versus Host Disease (GVHD) – Pipeline by apceth Biopharma GmbH

Table 40: Graft Versus Host Disease (GVHD) – Pipeline by Aptevo Therapeutics Inc

Table 41: Graft Versus Host Disease (GVHD) – Pipeline by Athersys Inc

Table 42: Graft Versus Host Disease (GVHD) – Pipeline by Bellicum Pharmaceuticals Inc

Table 43: Graft Versus Host Disease (GVHD) – Pipeline by Biogen Inc

Table 44: Graft Versus Host Disease (GVHD) – Pipeline by Bristol-Myers Squibb Co

Table 45: Graft Versus Host Disease (GVHD) – Pipeline by Capricor Therapeutics Inc

Table 46: Graft Versus Host Disease (GVHD) – Pipeline by Cell2B Advanced Therapeutics SA

Table 47: Graft Versus Host Disease (GVHD) – Pipeline by Cellect Biotechnology Ltd

Table 48: Graft Versus Host Disease (GVHD) – Pipeline by Cellective BioTherapy Inc

Table 49: Graft Versus Host Disease (GVHD) – Pipeline by CSL Ltd

Table 50: Graft Versus Host Disease (GVHD) – Pipeline by Cynata Therapeutics Ltd

Table 51: Graft Versus Host Disease (GVHD) – Pipeline by Cytodyn Inc

Table 52: Graft Versus Host Disease (GVHD) – Pipeline by Elsalys Biotech SA

Table 53: Graft Versus Host Disease (GVHD) – Pipeline by enGene Inc

Table 54: Graft Versus Host Disease (GVHD) – Pipeline by Enlivex Therapeutics Ltd

Table 55: Graft Versus Host Disease (GVHD) – Pipeline by F. Hoffmann-La Roche Ltd

Table 56: Graft Versus Host Disease (GVHD) – Pipeline by Fate Therapeutics Inc

Table 57: Graft Versus Host Disease (GVHD) – Pipeline by Generon (Shanghai) Corp Ltd

Table 58: Graft Versus Host Disease (GVHD) – Pipeline by GlaxoSmithKline Plc

Table 59: Graft Versus Host Disease (GVHD) – Pipeline by Incyte Corp

Table 60: Graft Versus Host Disease (GVHD) – Pipeline by Inspyr Therapeutics Inc

Table 61: Graft Versus Host Disease (GVHD) – Pipeline by Jazz Pharmaceuticals Plc

Table 62: Graft Versus Host Disease (GVHD) – Pipeline by Johnson & Johnson

Table 63: Graft Versus Host Disease (GVHD) – Pipeline by Kadmon Corp LLC

Table 64: Graft Versus Host Disease (GVHD) – Pipeline by Kamada Ltd

Table 65: Graft Versus Host Disease (GVHD) – Pipeline by Kiadis Pharma NV

Table 66: Graft Versus Host Disease (GVHD) – Pipeline by Kymab Ltd

Table 67: Graft Versus Host Disease (GVHD) – Pipeline by LG Chem Ltd

Table 68: Graft Versus Host Disease (GVHD) – Pipeline by MaaT Pharma

Table 69: Graft Versus Host Disease (GVHD) – Pipeline by Magenta Therapeutics Inc

Table 70: Graft Versus Host Disease (GVHD) – Pipeline by MallInckrodt Plc

Table 71: Graft Versus Host Disease (GVHD) – Pipeline by Medicenna Therapeutics Corp

Table 72: Graft Versus Host Disease (GVHD) – Pipeline by Mesoblast Ltd

Table 73: Graft Versus Host Disease (GVHD) – Pipeline by Millennium Pharmaceuticals Inc

Table 74: Graft Versus Host Disease (GVHD) – Pipeline by Novartis AG

Table 75: Graft Versus Host Disease (GVHD) – Pipeline by OncoImmune Inc

Table 76: Graft Versus Host Disease (GVHD) – Pipeline by Pfizer Inc

Table 77: Graft Versus Host Disease (GVHD) – Pipeline by Pharmicell Co Ltd

Table 78: Graft Versus Host Disease (GVHD) – Pipeline by Pluristem Therapeutics Inc

Table 79: Graft Versus Host Disease (GVHD) – Pipeline by REGiMMUNE Corp

Table 80: Graft Versus Host Disease (GVHD) – Pipeline by Sanofi

Table 81: Graft Versus Host Disease (GVHD) – Pipeline by Seattle Genetics Inc

Table 82: Graft Versus Host Disease (GVHD) – Pipeline by Seres Therapeutics Inc

Table 83: Graft Versus Host Disease (GVHD) – Pipeline by Sublimity Therapeutics Ltd

Table 84: Graft Versus Host Disease (GVHD) – Pipeline by Syndax Pharmaceuticals Inc

Table 85: Graft Versus Host Disease (GVHD) – Pipeline by Takeda Pharmaceutical Co Ltd

Table 86: Graft Versus Host Disease (GVHD) – Pipeline by Targazyme Inc

Table 87: Graft Versus Host Disease (GVHD) – Pipeline by TC BioPharm Ltd

Table 88: Graft Versus Host Disease (GVHD) – Pipeline by TxCell SA

Table 89: Graft Versus Host Disease (GVHD) – Pipeline by United BioPharma Inc

Table 90: Graft Versus Host Disease (GVHD) – Pipeline by Vault Pharma Inc

Table 91: Graft Versus Host Disease (GVHD) – Pipeline by VBI Vaccines Inc

Table 92: Graft Versus Host Disease (GVHD) – Pipeline by Visterra Inc

Table 93: Graft Versus Host Disease (GVHD) – Pipeline by Xenikos BV

Table 94: Graft Versus Host Disease (GVHD) – Pipeline by XL-protein GmbH

Table 95: Graft Versus Host Disease (GVHD) – Pipeline by Zai Lab Ltd

Table 96: Liver Transplant Rejection – Pipeline by Alexion Pharmaceuticals Inc

Table 97: Liver Transplant Rejection – Pipeline by Dompe Farmaceutici SpA

Table 98: Liver Transplant Rejection – Pipeline by Novartis AG

Table 99: Liver Transplant Rejection – Pipeline by RedHill Biopharma Ltd

Table 100: Liver Transplant Rejection – Pipeline by Veloxis Pharmaceuticals A/S

Table 101: Kidney Transplant Rejection – Pipeline by Amgen Inc

Table 102: Kidney Transplant Rejection – Pipeline by Angion Biomedica Corp

Table 103: Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc

Table 104: Kidney Transplant Rejection – Pipeline by Balmes Transplantation SAS

Table 105: Kidney Transplant Rejection – Pipeline by Bioverativ Inc

Table 106: Kidney Transplant Rejection – Pipeline by Catalyst Biosciences Inc

Table 107: Kidney Transplant Rejection – Pipeline by CSL Ltd

Table 108: Kidney Transplant Rejection – Pipeline by Gilead Sciences Inc

Table 109: Kidney Transplant Rejection – Pipeline by Hansa Medical AB

Table 110: Kidney Transplant Rejection – Pipeline by Idogen AB

Table 111: Kidney Transplant Rejection – Pipeline by ITB-Med AB

Table 112: Kidney Transplant Rejection – Pipeline by Johnson & Johnson

Table 113: Kidney Transplant Rejection – Pipeline by Kyowa Hakko Kirin Co Ltd

Table 114: Kidney Transplant Rejection – Pipeline by Noorik Biopharmaceuticals AG

Table 115: Kidney Transplant Rejection – Pipeline by Novartis AG

Table 116: Kidney Transplant Rejection – Pipeline by Opsona Therapeutics Ltd

Table 117: Kidney Transplant Rejection – Pipeline by Pharmicell Co Ltd

Table 118: Kidney Transplant Rejection – Pipeline by Pharming Group NV

Table 119: Kidney Transplant Rejection – Pipeline by Prolong Pharmaceuticals LLC

Table 120: Kidney Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc

Table 121: Kidney Transplant Rejection – Pipeline by Shire Plc

Table 122: Kidney Transplant Rejection – Pipeline by TolerogenixX GmbH

Table 123: Kidney Transplant Rejection – Pipeline by TxCell SA

Table 124: Lung Transplant Rejection – Pipeline by Amgen Inc

Table 125: Lung Transplant Rejection – Pipeline by Kamada Ltd

Table 126: Lung Transplant Rejection – Pipeline by MimeTech Srl

Table 127: Lung Transplant Rejection – Pipeline by Novartis AG

Table 128: Lung Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc

Table 129: Lung Transplant Rejection – Pipeline by TxCell SA

Table 130: Graft Versus Host Disease (GVHD) – Dormant Projects

Table 131: Liver Transplant Rejection – Dormant Projects

Table 132: Kidney Transplant Rejection – Dormant Projects

Table 133: Lung Transplant Rejection – Dormant Projects

Table 134: Graft Versus Host Disease (GVHD) – Discontinued Products

Table 135: Liver Transplant Rejection – Discontinued Products

Table 136: Kidney Transplant Rejection – Discontinued Products

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards